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ABSTRACT: Almost all known members of the cytochrome P450 (CYP)
superfamily conserve a key cysteine residue that coordinates the heme iron.
Although mutation of this residue abolishes monooxygenase activity, recent work
has shown that mutation to either serine or histidine unlocks non-natural carbene-
and nitrene-transfer activities. Here we present the ﬁrst crystal structure of a
histidine-ligated P450. The T213A/C317H variant of the thermostable CYP119
from Sulfolobus acidocaldarius maintains heme iron coordination through the
introduced ligand, an interaction that is accompanied by large changes in the overall
protein structure. We also ﬁnd that the axial cysteine C317 may be substituted with
any other amino acid without abrogating folding and heme cofactor incorporation.
Several of the axial mutants display unusual spectral features, suggesting that they
have active sites with unique steric and electronic properties. These novel, highly
stable enzyme active sites will be fruitful starting points for investigations of non-
natural P450 catalysis and mechanisms.
■ INTRODUCTION
Axial ligation to the iron center is the principal mechanism
through which hemoproteins tune the electronic properties of
the heme cofactor, with a diverse set of amino acid residues
(His, Tyr, Met, Lys, and Cys) called upon to act as ligands in
naturally occurring hemoproteins.1 Among cytochrome P450s
(CYPs), axial thiolate ligation plays a key role at several points
during the catalytic cycle. Thiolate ligation enables redox-gating
of oxygen activation,2 favors O−O bond heterolysis rather than
homolysis,3 and markedly enhances the basicity of compound
II,4 which favors hydrogen atom abstraction chemistry rather
than 1e− oxidations typical of peroxidases. Although the Cys at
the axial position is almost universally conserved among known
naturally occurring P450s, a few engineered proteins with
mutations at this position have been characterized as
mechanistic probes of P450 monooxygenase chemistry.5 P450
axial mutants no longer catalyze monooxygenation and are also
frequently impaired with respect to heme incorporation and
soluble expression. Recently, this laboratory has shown that
mutation of the axial ligand in several P450s strongly promotes
non-natural carbene- and nitrene-transfer activities in the
presence of carbene and nitrene precursors and suitable
acceptor substrates.6 The conservative Cys-to-Ser substitution
increases those activities, particularly in whole E. coli cells.6 An
axial histidine mutant of P450BM3 was also shown to be highly
active as a carbene-transfer catalyst.7
The similar sizes and side-chain functionalities of Ser and Cys
would suggest that Ser coordinates in the same way as the
native Cys ligand, and indeed, this has been conﬁrmed in the X-
ray crystal structures of two variants of P450BM3 containing the
axial Cys-to-Ser mutation.6a,8 The hemes are superimposable in
the Cys- and Ser-ligated structures, and there is no change in
the conformation of the proximal loop that contains the axial
ligand. In contrast, it is diﬃcult to envision how the proximal
pocket can accommodate heme coordination by the much
bulkier side chain of histidine. In fact, previous attempts to
prepare P450 axial variants with bulky ligands such as His or
Tyr have resulted in low expression and poor heme
incorporation,5a−c,9 perhaps owing to unfavorable steric
interactions imposed by these residues.
Despite longstanding interest in the structures of P450 axial
mutants speciﬁcally and P450 structure and function more
generally,10 no X-ray crystal structural data have been reported
that reveal how the protein maintains heme binding and
ligation when the axial Cys is substituted by an amino acid of
such diﬀerent size and chemical properties. Given the
fundamental interest in exploring how enzyme active sites
may be retuned for alternative catalytic functions, either in
nature or the laboratory and the fact that accurate structural
data are often vital to successful engineering eﬀorts, we sought
to determine the structure of an axial Cys-to-Ser mutant of a
CYP. Because thermophilic enzymes have a greater tendency to
yield high-quality protein crystals suitable for X-ray crystallog-
raphy, we chose to focus our eﬀorts on the highly thermostable
and well-studied CYP119 from S. acidocaldarius.11 Here we
describe the crystal structure of a histidine-ligated CYP119 and
show that histidine heme iron ligation is accompanied by large
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local and global conformational changes in the protein. We
further show that the universally conserved axial cysteine may
be substituted in CYP119 with any other amino acid without
abrogating heme incorporation or production of soluble
enzyme. These results demonstrate an impressive level of
structural adaptability in the P450 fold.
■ RESULTS AND DISCUSSION
We set out to crystallize the axial Cys-to-His single mutant
(C317H) of CYP119 as well as a variant containing an
additional mutation to the conserved distal threonine residue
(double mutant T213A/C317H). Mutations to both of these
conserved residues have been shown to be highly activating of
non-natural P450 catalysis.6,12 We were delighted when the
double mutant yielded protein crystals that diﬀracted to 2.7 Å
resolution, revealing an unusual conformation of the P450 fold
and the ﬁrst structure of a histidine-ligated P450.
We cocrystallized the T213A/C317H variant with the P450
inhibitor phenylimidazole used in the determination of the
crystal structure of wild-type CYP11911c so that we could
compare the two structures. In each of the four protein
molecules in the asymmetric unit of the T213A/C317H
structure, the heme is present and is clearly histidine-ligated,
with well-resolved electron density for H317 extending onto
the heme iron (Figure 1; structure statistics presented in Table
S1). Although there are some diﬀerences among the protomers,
each shows a signiﬁcant rearrangement of the proximal loop
where H317 resides. This movement of the backbone shifts Cα
of H317 by 1.2 Å away from the heme center (as measured to
the wild-type CYP119 Fe atom). However, the rearrangement
of the proximal loop alone is apparently insuﬃcient to
accommodate non-native ligation because histidine ligation
also induces a striking 17° tilt in the plane of the porphyrin ring
away from the axial residue (Figure 2A). The porphyrin tilt, in
turn, requires a large compensating adjustment by the protein
backbone in order to maintain coordination of the heme
propionate side-chains. The interaction between the heme 7-
propionate and R259 of the protein is easily accommodated by
alternate rotamers of the heme propionates and enzyme amino
acid side-chains (Figure 2B), which apparently obviate the need
for any large-scale movement in the β sheet that contains R259.
In contrast, there is a large adjustment of the C helix, in which
sits a key histidine residue (H76) that forms a salt bridge to the
heme 6-propionate at a distance of 2.8 Å in the wild-type
structure (Figure 2A). This salt bridge is maintained in 2 out of
4 protomers in the mutant structure via a 7 Å displacement of
the C helix (measured from Cα to Cα). This interaction is not
observed in the other two protomers because of increased
disorder in the C helix. Additionally, H315, which in the wild-
type structure also forms a salt bridge to the heme 6-propionate
at a distance of 2.7 Å, is shifted by 4 Å in the structure of the
double mutant (Cα−Cα). As a result, this interaction is
signiﬁcantly longer in the mutant structure (4.5 Å).
These local perturbations are ampliﬁed at a global level,
leading to signiﬁcant distortions of the overall structure of the
double mutant relative to that of wild type (Figure 3).
Comparison of the gross conformational changes between wild-
type CYP119 and its T213A/C317H variant is highly
dependent upon the method used to superimpose the two
structures. Nevertheless, least-squares (LSQ) alignment across
all Cα atoms reveals that the wild-type and mutant structures
diﬀer by an astounding 4.7 Å RSMD.
Several portions of the protein are unresolved in the T213A/
C317H structure, including the F−G loop as well as the F and
B′ helices, which are resolved in the wild-type structure 1F4T.
Perhaps the most dramatic change is observed in the G helix,
which is displaced by 14 Å in a hingelike movement away from
the heme relative to the wild-type 4-phenylimidazole-bound
structure (presumed to be a closed conformation). This shift is
very diﬀerent from the open−closed conformational motion of
wild-type CYP119, which involves a signiﬁcant movement (>10
Å) of the F−G loop but a relatively minor hingelike movement
of the G helix (∼1 Å shift measured from K166 Cα−Cα using
4-phenylimidazole-bound (1F4T) and substrate-free (1IO7)
structures).11c,13 In contrast, CYP119 T213A/C317H under-
goes a much more signiﬁcant hingelike movement of the G
helix relative to that of the wild-type inhibitor-bound structure
(14 Å as measured from K166 Cα−Cα), perhaps resulting from
the signiﬁcant adjustment forced by the porphyrin tilt.
Figure 1. His coordination of heme center in CYP119 T213A/
C317H.
Figure 2. (A) His coordination of 6-propionate in wild-type CYP119
(gray) and T213A/C317H mutant (blue). (B) Arg coordination of 7-
propionate in wild type (gray) and T213A/C317H mutant (blue).
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Also unusual is the reorientation of the H helix and complete
removal of the kink in the I helix, which results in a roughly 8 Å
hinge movement at the beginning of the helix. Within the
portion of the I helix that is closest to the heme also containing
the T213A mutation, the helix geometry is very diﬀerent from
that of wild type. In particular, several water molecules are
inserted within the I helix of the wild-type protein that disrupt
direct intrahelix hydrogen bonds. In the His-ligated structure,
the helix has expelled these waters and shifted register by a full
residue to facilitate new direct backbone−backbone N−H·O
C hydrogen bonds (Figure 4). It is tempting to attribute the I-
helix changes to the distal T213A mutation, but previous
structures of P450s containing distal threonine-to-alanine
mutations (T213A equivalent) are virtually superimposable
with corresponding wild-type structures, both globally and
locally. For example, P450BM3 and its distal threonine T268A
mutant (2IJ2 and 1YQO, respectively) diﬀer by a RMSD of 0.5
Å, whereas P450nor and its T243A mutant (1ROM and 1F24,
respectively) diﬀer by 0.4 Å. If we consider only the I helix,
then the divergences in previously described distal threonine
mutants appear even smaller: 0.2 Å for P450BM3 and its T268A
mutant and 0.3 Å for P450nor and its T243A mutant. In
contrast, the T213A/C317H structure shows a much greater
distortion within the I helix (RMSD of 3.2 Å relative to wild
type using only backbone atoms), which strongly suggests that
the observed eﬀect on the I helix is due to the axial mutation
and the accompanying porphyrin tilt. Notably, the heme
cofactor would clash with the I helix in its tilted state if there
were not some compensatory change in the protein structure;
the T213A mutation may enable this movement to some
degree (see below).
On the whole, large distortions in the overall fold observed in
the T213A/C317H structure point to an impressive ﬂexibility
in the P450 fold that allows it to accommodate what would
seem to be a highly disruptive mutation at the axial position.
Reasoning that other substitutions should also be tolerated, we
generated all possible single-axial mutants of wild-type CYP119
and expressed and puriﬁed the resulting proteins. To our
surprise, all 19 possible substitutions at the universally
conserved axial position resulted in expression of heme-
containing holoprotein.
We ﬁrst characterized the ferric, ferrous, and ferrous CO-
bound spectra of the axial variants by UV−vis spectroscopy to
determine whether we could discern diﬀerent active site
coordination environments. On the basis of these data, we
grouped the axial mutants into two broad categories. The ﬁrst
group (C317A/G/S/T) displayed UV−vis spectral properties
distinct from those of the His-ligated T213A/C317H enzyme
as well as from one another. (Complete spectra are presented
in Table S2 and Figure S1.) Particularly striking are the
diﬀerences between the C317A and C317G variants because
one might intuitively expect both to be water-ligated and thus
to evince very similar spectra. However, the C317A and C317G
enzymes are spectrally diﬀerent from one another and from
previously characterized Ala and Gly hemoprotein mutants.14
Figure 3. Overall structure of CYP119 T213A/C317H (left, blue) and wild-type CYP119 (right, gray) with selected helices labeled; only regions that
are structured in the mutant are shown in the wild-type structure.
Figure 4. I-helix structure for (A) CYP119 T213A/C317H mutant
(PDB: 5BV5) and (B) wild type (PDB: 1F4T) showing ordered
waters in wild-type structure and the compression and register shift of
the I helix in the T213A/C317H mutant. Iron atom shown as van der
Waals sphere; phenylimidazole inhibitor not shown for clarity.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.5b07107
J. Am. Chem. Soc. 2015, 137, 13861−13865
13863
The C317A variant has a dark-brown color, a ferric Soret
maximum at 405 nm, and a featureless α,β region. This variant
also has an extremely blue-shifted ferrous CO-bound Soret
maximum at 400 nm. C317G, by contrast, is bright red and has
a ferrous CO Soret peak at 414 nm. In the ferric state, C317G
has well-resolved α and β bands, suggesting either a mixed- or
low-spin heme state.14a Axial serine and threonine variants also
have distinct spectra, though both are fairly similar to those of
previously described axial serine mutants.5a,b,6a,9,15 In particular,
C317S showed a roughly 5 nm blueshift in the ferric and
ferrous CO-bound states relative to C317T.
The second group, which encompasses the majority of the
axial variants, had ferric, ferrous, and ferrous CO-bound spectra
that were quite similar to those of the structurally characterized
histidine-ligated T213A/C317H double mutant and the C317H
single mutant (Figure S1). These observations suggest that
these C317X variants undergo a rearrangement within the
proximal heme pocket that results in an alternative residue,
presumably a histidine, assuming the coordinating role. Such
rearrangements have been invoked to explain the observation of
inactive “P420” preparations giving ferrous CO-bound Soret
peaks at ∼420 nm.16 Indeed, like many other P450 enzymes,
CYP119 has a histidine (H315) two residues upstream from
the axial cysteine; H315 is a likely suspect for this alternative
coordinating ligand.
Having observed the apparent resilience of CYP119 to
mutation at C317, we wished to determine the eﬀects of the
C317X mutations on protein stability and cofactor incorpo-
ration. Relative levels of heme incorporation were measured by
taking the ratio of the 276 nm (protein) and 395 nm (heme)
absorbance for acid-denatured CYP119 variants. (See Support-
ing Information for assay description.) Surprisingly, we found
that many of the C317X variants incorporated heme at levels
even higher than did the wild-type enzyme, whereas a few
showed lower levels (Table S3). Previous reports have noted
that wild-type P450 and other hemoprotein preparations often
contain a signiﬁcant fraction of apoprotein,17 consistent with
our observation of incomplete heme incorporation in wild type
CYP119.
All 19 axial mutants of CYP119 were less thermostable than
the wild-type enzyme, as measured by T50, the temperature at
which half the protein is irreversibly denatured after a 10 min
incubation (Table S4 and Figure S2). The maximum
destabilization was 8 °C in T50 for C317A relative to that of
wild type (T50 = 84.6 °C), with an average loss of ∼6 °C. The
T213A/C317H double mutant experiences a relatively small
loss of 1.2 °C in its T50, despite the very signiﬁcant structural
distortion. Although the T213A mutation has a slight stabilizing
eﬀect (+1.1 °C relative to that of wild type), it is signiﬁcantly
more stabilizing in the context of the C317H mutant (+4.9 °C).
This suggests that the T213A mutation indeed serves to reduce
a steric clash between the porphyrin and the I helix and to
compensate for the C317H substitution in the T213A/C317H
double mutant.
The exceptional thermostability of CYP119 undoubtedly
aided our eﬀorts to determine the eﬀects of axial mutations on
the P450 structure and spectral properties by providing a buﬀer
for the signiﬁcantly destabilizing eﬀects of the axial mutations.
Making corresponding axial mutations in mesophilic P450
enzymes, many of which are only marginally stable, may be
challenging unless compensatory mutations (such as the distal
threonine-to-alanine mutation) are also included. Indeed,
P450cam axial histidine mutants are much more diﬃcult to
prepare than the corresponding wild-type enzyme, requiring
either enzyme refolding5e or reconstitution.5d Even where bulky
axial substitutions are reasonably well-tolerated, as in
P450BM3,7 they may lead to increased conformational
heterogeneity, making structural determination especially
challenging. In fact, despite repeated eﬀorts, we have been
unable to obtain crystal structures of P450BM3 axial histidine
mutants.
■ CONCLUSIONS
CYP119 accommodates heme iron coordination by the bulky
histidyl side chain with a large tilt in the porphyrin ring and a
signiﬁcant rearrangement in the overall protein fold. Despite
this, the His-ligated protein is still highly thermostable and
eﬃciently incorporates heme. Given the impressive adaptability
of the P450 fold revealed by this structure, we generated all 19
possible axial mutants of CYP119 and found that they could all
be isolated as heme-containing holoproteins. This result further
underscores the high degree of structural adaptability in the
P450 fold.
It was believed until recently that the axial Cys ligand was
universally conserved among CYPs. Several P450 sequences
have been identiﬁed, however, that appear to lack an axial
cysteine,18 which means that there is not a single universally
conserved motif or residue in the vast and functionally diverse
CYP superfamily.18a Although the structures and functions of
these putative non-Cys-ligated CYPs are unknown, it is likely
that new chemistry remains to be discovered among nature’s
astonishing CYP diversity. Meanwhile, the beneﬁcial eﬀects of
P450 axial mutations in conferring non-natural carbene- and
nitrene-transfer activities6,7,10b clearly demonstrates the ability
of this scaﬀold to take on new functions. Having all the axial
mutants of CYP119 will allow exploration of a greater range of
structural and heme electronic properties than has been
possible in the past; we anticipate that this will facilitate the
continued expansion of P450 catalysis.
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